DOCSLIB.ORG

Structure-Based Virtual Screening of Human Β-Glucuronidase Inhibitors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Research Article ISSN: 2574 -1241 DOI: 10.26717/BJSTR.2021.35.005677 Structure-Based Virtual Screening of Human β-Glucuronidase Inhibitors Sumera Zaib1*, Hadiqa Aimen2, Urooj Yousaf Virk1, Aliya Ibrar3, Asma Gul2, Muhammad Naveed4 and Imtiaz Khan5* 1Department of Biochemistry, Faculty of Life Sciences, University of Central Punjab, Pakistan 2Department of Biological Sciences, International Islamic University, Pakistan 3Department of Chemistry, Faculty of Natural Sciences, The University of Haripur, Pakistan 4Department of Biotechnology, Faculty of Life Sciences, University of Central Punjab, Pakistan 5Manchester Institute of Biotechnology, The University of Manchester, 131 Princess Street, Manchester M1 7DN, United Kingdom *Corresponding authors: Imtiaz Khan, Manchester Institute of Biotechnology, The University of Manchester, 131 Princess Street, Manchester M1 7DN, United Kingdom. Sumera Zaib, Department of Biochemistry, Faculty of Life Sciences, University of Central Punjab, Lahore-54590, Pakistan ARTICLE INFO ABSTRACT Received: April 14, 2021 Beta-glucuronidase is an important enzyme involved in the digestion, particularly Published: April 22, 2021 environmental toxins. Taking this into consideration, the present study was designed toin selectphase and2 of identifyliver detoxification potential scaffolds especially followed in detoxifying by beta-glucuronidase estrogen like hormonesinhibition and computational studies. Six different types of scaffolds were selected based on their Citation: Sumera Zaib, Hadiqa Aimen, potential to interact therapeutically with beta-glucuronidase enzyme. Among them, Urooj Yousaf Virk, Aliya Ibrar, Asma the most potent compound was subjected to molecular docking studies and the results Gul, Muhammad Naveed, Imtiaz Khan. Structure-Based Virtual Screening of site of beta-glucuronidase. Some compounds identical to marketed inhibitors of beta- revealed significant interactions with important amino acid residues within the active Human β-Glucuronidase Inhibitors. Biomed J Sci & Tech Res 35(2)-2021. was generated. The pharmacophore method was applied for the screening of potent glucuronidase were retrieved from PubChem and Zinc database, and a defined library BJSTR. MS.ID.005677. inhibitor of beta-glucuronidase. Structural similarity search feature assembled a total Keywords: Beta-Glucuronidase; Library the already reported methods. These investigations can be used in the design of selective - of >500 compounds. Out of which 9 compounds were selected and filtered out applying ing; Molecular Docking Design; Inhibitory Efficacy; Virtual Screen advancedβ-glucuronidase studies. inhibitors for future studies. This analysis may lead to findings for novel β-glucuronidase inhibitors against digestion related disorders after some more Introduction Glycosidase Family of Enzymes at specific glucuronide site [2]. These specific enzymes are found Glycosidases (GH) are vital for almost all living organisms categorized as one of the key enzymes for the treatment of numerous (exceptions are some Archaeans and a few unicellular parasitic in plants, bacteria and vertebrates. Intestinal β-glucuronidase is eukaryotes) playing diverse and different roles. Considering sp (Ampullaria and Helix pomatia) are used in the hydrolysis of intestinal diseases. In invertebrates, β-glucuronidase from mollusk the diversity of reactions, they catalyze, amino acid sequence steroids in order to assess urinary conjugate cortisol [3]. Besides categories [1]. been found active in acidic condition (pH ~ 4-5). It has also been and folding, glycosidases have been classified in many different intestinal β-glucuronidase, the lysosomal β-glucuronidase have Beta-Glucuronidases observed that there is a direct effect of pH and temperature on the glycosidase that have role in the hydrolysis of glycosaminoglycans stability of enzyme. The stability of β-glucuronidase is determined Beta-glucuronidase (β-glucuronidase) enzyme (EC3.2.1.31) is a standard (37 °C) and optimum temperature (70 °C). At both and confirmed by residual activity at varying temperature of Copyright@ Sumera Zaib, Imtiaz Khan | Biomed J Sci & Tech Res | BJSTR. MS.ID.005677. 27515 Volume 35- Issue 2 DOI: 10.26717/BJSTR.2021.35.005677 temperatures, the enzymes have a positive response from acidic mass of 50 KDa [7]. to neutral pH. At 75 °C temperature and pH above 8, the activity Structure of Beta-Glucuronidases carbohydrate processing. Human beta-glucuronidase is found to be as 80 kDa in of enzyme is lost [3]. Other key roles of β-glucuronidase includes monomeric form (653 amino acids residues) and its proteolysis They also show functional importance and are used in the cleaves 18 amino acid residues from the carboxy terminal end hydrolysis of various steroids, bioassay for plant hormones, leaving it as 78 kDa monomer. It exists in homotetrameric form prodrug therapy [4] and as biomarker [5] and are present in with 332 kDa while carrying various notable structural changes, including beta barrel type, also known as a jelly-roll barrel, and extracellular fluid during the inflammation [6]. In human plasma, the TIM barrel [8]. The crystal structure of the enzyme has been β-glucuronidase serves as a biomarker for the identification this enzyme can lead to autosomal recessive disorders which is of human exposure to organophosphate [4]. The deficiency of mucopolysaccharidosis VII, commonly known as Sly syndrome solved by X-ray crystallography. The specific site for the transport (MPR) [9]. of lysosomal β-glucuronidase is mannose 6-phosphate receptor (GUSB) plays an important role in various applications of plant Chromosomal Location of Beta-Glucuronidases GAUSB [4]. Genetic studies have revealed that β-glucuronidase gene Gene biotechnology. β-Glucuronidase proteins have also been developed Its cytogenetic location is 7q11.21, on the long (q) arm of replacement therapy). The protein, isolated from most vertebrates, by cloning, expression and purification of enzymes (enzyme chromosome, number 7 at 11.21 position (Figure 1) while its occurs in the form of homotetramers with a molecular mass of molecular location is 65,960,684 to 65,982,314 base pairs on chromosome number 7 (Homo sapiens Annotation Release 109, by various chromatographic techniques possesses a molecular around 280-300 KDa while the lysosomal β-glucuronidase purified GRCh38.p12) (NCBI). Figure 1: Chromosomal location of GAUSB gene (NCBI). Beta-glucuronidase and Diseases Computational Screening In 2000, Sperker et al. addressed the least investigated issue Virtual screening (VS) is a powerful computer-based technique regarding the excess release of beta-glucuronidase in pancreatic cancer [10]. This fatal pancreatic cancer is world’s 5th cause which has widely been used for the identification of promising of death. This study illustrated the excess release of enzyme by with known molecular target structures. VS is considered as an compounds such as specific inhibitors that are capable of binding carcinoma cells as compared to normal cells. It is also up regulated in imperative technique, for new inhibitors and molecular drug different pathological diseases like urinary tract infection and renal discovery, depending upon the growing demand of protein and diseases. It also causes transplant rejection, epilepsy and cancers nucleic acid structure. Virtual screening evaluates numerous i-e., breast and larynx cancer. Moreover, it is involved in the bone understood and perceived for this purpose. Primary concern is compounds all at once, two significant steps should be well arthritis, and several hepatic diseases, and later acquired related disorders like inflammatory joint disorder and rheumatoid to find docking technique which will enable us to acquire our experiments of redocking are accomplished, where separation of immunodeficiency syndrome which is linked to the overexpression desired configuration [13]. To justify a docking method, various whole series of known complexes are completed followed by the of beta-glucuronidase [11]. In many tumors and inflammatory into the extracellular space [10]. Since then, the researchers started process of redocking. The secondary concern is to assure whether areas, β-glucuronidase activity is high and the enzyme is secreted focusing the inhibition of beta-glucuonidase enzyme through the this docking strategy will be able to replicate the detected binding development of various inhibitors mainly nitrogen heterocyclic mode. Through these validation studies, nearly 10 degree of compounds such as indole, triazoles and benzothiazole [12]. torsional freedom was found in drug like molecules of recent version Copyright@ Sumera Zaib, Imtiaz Khan | Biomed J Sci & Tech Res | BJSTR. MS.ID.005677. 27516 Volume 35- Issue 2 DOI: 10.26717/BJSTR.2021.35.005677 of Auto-Dock. Furthermore, next step is to ensure experimentally Docking Based Screening (DBVS) that the compounds do bound at their predicted binding energy, allowing precise grading of compounds [13]. presented below functions normally using targeted structure The workflow chart for docking-based virtual screening (DBVS) for input, which can be modelled experimentally or on computer of energy prediction through computational based docking basis together with small-molecules containing compound library Solely standard deviation of 2-3 Kcal/mol, provides efficiency which is either purchased or synthesized (Figure 2). Proper ranking though. The compound enrichment process is implied assignment of protonation, tautomeric, and stereoisomeric states algorithms
Recommended publications
  • Structure-Based Virtual Screening of Hypothetical Inhibitors of the Enzyme Longiborneol Synthase—A Potential Target to Reduce Fusarium Head Blight Disease

    Structure-Based Virtual Screening of Hypothetical Inhibitors of the Enzyme Longiborneol Synthase—A Potential Target to Reduce Fusarium Head Blight Disease

    J Mol Model (2016) 22: 163 DOI 10.1007/s00894-016-3021-1 ORIGINAL PAPER Structure-based virtual screening of hypothetical inhibitors of the enzyme longiborneol synthase—a potential target to reduce Fusarium head blight disease E. Bresso1 & V. L ero ux 2 & M. Urban3 & K. E. Hammond-Kosack3 & B. Maigret2 & N. F. Martins1 Received: 17 December 2015 /Accepted: 27 May 2016 /Published online: 21 June 2016 # Springer-Verlag Berlin Heidelberg 2016 Abstract Fusarium head blight (FHB) is one of the most compounds from a library of 15,000 drug-like compounds. destructive diseases of wheat and other cereals worldwide. These putative inhibitors of longiborneol synthase provide a During infection, the Fusarium fungi produce mycotoxins that sound starting point for further studies involving molecular represent a high risk to human and animal health. Developing modeling coupled to biochemical experiments. This process small-molecule inhibitors to specifically reduce mycotoxin could eventually lead to the development of novel approaches levels would be highly beneficial since current treatments to reduce mycotoxin contamination in harvested grain. unspecifically target the Fusarium pathogen. Culmorin pos- sesses a well-known important synergistically virulence role Keywords Fusarium mycotoxins . Culmorin . Inhibitors . among mycotoxins, and longiborneol synthase appears to be a Homology modeling . Molecular dynamics . Ensemble key enzyme for its synthesis, thus making longiborneol syn- docking thase a particularly interesting target. This study aims to dis- cover potent and less toxic agrochemicals against FHB. These compounds would hamper culmorin synthesis by inhibiting Introduction longiborneol synthase. In order to select starting molecules for further investigation, we have conducted a structure- Fusarium head blight (FHB), caused by Fusarium based virtual screening investigation.
  • Virtual Screening of the Inhibitors Targeting at the Viral Protein 40 of Ebola Virus V

    Virtual Screening of the Inhibitors Targeting at the Viral Protein 40 of Ebola Virus V

    Karthick et al. Infectious Diseases of Poverty (2016) 5:12 DOI 10.1186/s40249-016-0105-1 RESEARCH ARTICLE Open Access Virtual screening of the inhibitors targeting at the viral protein 40 of Ebola virus V. Karthick1, N. Nagasundaram1, C. George Priya Doss1,2, Chiranjib Chakraborty1,3, R. Siva4, Aiping Lu1, Ge Zhang1 and Hailong Zhu1* Abstract Background: The Ebola virus is highly pathogenic and destructive to humans and other primates. The Ebola virus encodes viral protein 40 (VP40), which is highly expressed and regulates the assembly and release of viral particles in the host cell. Because VP40 plays a prominent role in the life cycle of the Ebola virus, it is considered as a key target for antiviral treatment. However, there is currently no FDA-approved drug for treating Ebola virus infection, resulting in an urgent need to develop effective antiviral inhibitors that display good safety profiles in a short duration. Methods: This study aimed to screen the effective lead candidate against Ebola infection. First, the lead molecules were filtered based on the docking score. Second, Lipinski rule of five and the other drug likeliness properties are predicted to assess the safety profile of the lead candidates. Finally, molecular dynamics simulations was performed to validate the lead compound. Results: Our results revealed that emodin-8-beta-D-glucoside from the Traditional Chinese Medicine Database (TCMD) represents an active lead candidate that targets the Ebola virus by inhibiting the activity of VP40, and displays good pharmacokinetic properties. Conclusion: This report will considerably assist in the development of the competitive and robust antiviral agents against Ebola infection.
  • Report on an NIH Workshop on Ultralarge Chemistry Databases Wendy A

    Report on an NIH Workshop on Ultralarge Chemistry Databases Wendy A

    1 Report on an NIH Workshop on Ultralarge Chemistry Databases Wendy A. Warr Wendy Warr & Associates, 6 Berwick Court, Holmes Chapel, Cheshire, CW4 7HZ, United Kingdom. Email: [email protected] Introduction The virtual workshop took place on December 1-3, 2020. It was aimed at researchers, groups, and companies that generate, manage, sell, search, and screen databases of more than one billion small molecules (Figure 1). There were about 550 “attendees” from 37 different countries. Recent advances in computational chemistry have enabled researchers to navigate virtual chemical spaces containing billions of chemical structures, carrying out similarity searches, studying structure-activity relationships (SAR), experimenting with scaffold-hopping, and using other drug discovery methodologies.1 For clarity, one could differentiate “spaces” from “libraries”, and “libraries” from “databases”. Spaces are combinatorially constructed collections of compounds; they are usually very big indeed and it is not possible to enumerate all the precise chemical structures that are covered. Libraries are enumerated collections of full structures: usually fewer than 1010 molecules. Databases are a way to storing libraries, for example, in a relational database management system. Figure 1. Ultralarge chemical databases. (Source: Marcus Gastreich based on the publication by Hoffmann and Gastreich.) This report summarizes talks from about 30 practitioners in the field of ultralarge collections of molecules. The aim is to represent as accurately as possible the information that was delivered by the speakers; the report does not seek to be evaluative. 2 Welcoming remarks; defining a drug discovery gateway Susan Gregurick, Office of Data Science and Strategy, NIH, USA Data should be “findable, accessible, interoperable and reusable” (FAIR)2 and with this in mind, NIH has been creating, curating, integrating, and querying ultralarge chemistry databases.
  • Qsar Methods Development, Virtual and Experimental Screening for Cannabinoid Ligand Discovery

    Qsar Methods Development, Virtual and Experimental Screening for Cannabinoid Ligand Discovery

    QSAR METHODS DEVELOPMENT, VIRTUAL AND EXPERIMENTAL SCREENING FOR CANNABINOID LIGAND DISCOVERY by Kyaw Zeyar Myint BS, Biology, BS, Computer Science, Hampden-Sydney College, 2007 Submitted to the Graduate Faculty of School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2012 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE This dissertation was presented by Kyaw Zeyar Myint It was defended on August 20th, 2012 and approved by Dr. Ivet Bahar, Professor, Department of Computational and Systems Biology Dr. Billy W. Day, Professor, Department of Pharmaceutical Sciences Dr. Christopher Langmead, Associate Professor, Department of Computer Science, CMU Dissertation Advisor: Dr. Xiang-Qun Xie, Professor, Department of Pharmaceutical Sciences ii Copyright © by Kyaw Zeyar Myint 2012 iii QSAR METHODS DEVELOPMENT, VIRTUAL AND EXPERIMENTAL SCREENING FOR CANNABINOID LIGAND DISCOVERY Kyaw Zeyar Myint, PhD University of Pittsburgh, 2012 G protein coupled receptors (GPCRs) are the largest receptor family in mammalian genomes and are known to regulate wide variety of signals such as ions, hormones and neurotransmitters. It has been estimated that GPCRs represent more than 30% of current drug targets and have attracted many pharmaceutical industries as well as academic groups for potential drug discovery. Cannabinoid (CB) receptors, members of GPCR superfamily, are also involved in the activation of multiple intracellular signal transductions and their endogenous ligands or cannabinoids have attracted pharmacological research because of their potential therapeutic effects. In particular, the cannabinoid subtype-2 (CB2) receptor is known to be involved in immune system signal transductions and its ligands have the potential to be developed as drugs to treat many immune system disorders without potential psychotic side- effects.
  • Fast Three Dimensional Pharmacophore Virtual Screening of New Potent Non-Steroid Aromatase Inhibitors

    Fast Three Dimensional Pharmacophore Virtual Screening of New Potent Non-Steroid Aromatase Inhibitors

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE J. Med. Chem. 2009, 52, 143–150 143 provided by Estudo Geral Fast Three Dimensional Pharmacophore Virtual Screening of New Potent Non-Steroid Aromatase Inhibitors Marco A. C. Neves,† Teresa C. P. Dinis,‡ Giorgio Colombo,*,§ and M. Luisa Sa´ e Melo*,† Centro de Estudos Farmaceˆuticos, Laborato´rio de Quı´mica Farmaceˆutica, Faculdade de Farma´cia, UniVersidade de Coimbra, 3000-295, Coimbra, Portugal, Centro de Neurocieˆncias, Laborato´rio de Bioquı´mica, Faculdade de Farma´cia, UniVersidade de Coimbra, 3000-295, Coimbra, Portugal, and Istituto di Chimica del Riconoscimento Molecolare, CNR, 20131, Milano, Italy ReceiVed July 28, 2008 Suppression of estrogen biosynthesis by aromatase inhibition is an effective approach for the treatment of hormone sensitive breast cancer. Third generation non-steroid aromatase inhibitors have shown important benefits in recent clinical trials with postmenopausal women. In this study we have developed a new ligand- based strategy combining important pharmacophoric and structural features according to the postulated aromatase binding mode, useful for the virtual screening of new potent non-steroid inhibitors. A small subset of promising drug candidates was identified from the large NCI database, and their antiaromatase activity was assessed on an in vitro biochemical assay with aromatase extracted from human term placenta. New potent aromatase inhibitors were discovered to be active in the low nanomolar range, and a common binding mode was proposed. These results confirm the potential of our methodology for a fast in silico high-throughput screening of potent non-steroid aromatase inhibitors. Introduction built and proved to be valuable in understanding the binding 14-16 Aromatase, a member of the cytochrome P450 superfamily determinants of several classes of inhibitors.
  • Bigger Is Better in Virtual Drug Screens

    Bigger Is Better in Virtual Drug Screens

    NEWS & VIEWS RESEARCH might no longer be elusive, but the nitrogen Doney, S. C. Biogeosciences 11, 691–708 (2014). cycle remains a treasure trove for discovery. ■ 6. Knapp, A. N., Casciotti, K. L., Berelson, W. M., Prokopenko, M. G. & Capone, D. G. Proc. Natl Acad. Sci. USA 113, 4398–4403 (2016). Nicolas Gruber is at the Institute of 7. Bonnet, S., Caffin, M., Berthelot, H. & Moutin, T. Biogeochemistry and Pollutant Dynamics, Proc. Natl Acad. Sci. USA 114, E2800–E2801 (2017). ETH Zurich, 8092 Zurich, Switzerland. 8. Wang, W.-L., Moore, J. K., Martiny, A. C. & e-mail: [email protected] Primeau, F. W. Nature 566, 205–211 (2019). 9. DeVries, T. & Primeau, F. J. Phys. Oceanogr. 41, 1. Redfield, A. C. in James Johnstone Memorial Volume 2381–2401 (2011). (ed. Daniel, R. J.) 176–192 (Univ. College Liverpool, 10. Gruber, N. in Nitrogen in the Marine Environment 50 Years Ago 1934). 2nd edn (eds Capone, D. G., Bronk, D. A., 2. Carpenter, E. J. & Capone, D. G. in Nitrogen in the Mulholland, M. R. & Carpenter, E. J.) 1–150 Test tube babies may not be just Marine Environment 2nd edn (eds Capone, D. G., (Elsevier, 2008). Bronk, D. A., Mulholland, M. R. & Carpenter, E. J.) 11. Yang, S., Gruber, N., Long, M. C. & Vogt, M. Glob. round the corner, but the day 141–198 (Elsevier, 2008). Biogeochem. Cycles 31, 1470–1487 (2017). when all the knowledge necessary 3. Gruber, N. Proc. Natl Acad. Sci. USA 113, 12. Kim, I.-N. et al. Science 346, 1102–1106 (2014). to produce them will be available 4246–4248 (2016).
  • Autodock Vina Manual

    Autodock Vina Manual

    4/21/2021 AutoDock Vina - molecular docking and virtual screening program Home Features Download Tutorial FAQ Manual Questions? AutoDock Vina Manual Contents Features License Tutorial Frequently Asked Questions Platform Notes and Installation Windows Linux Mac Building from Source Other Software Usage Summary Configuration File Search Space Exhaustiveness Output Advanced Options Virtual Screening History Citation Getting Help Reporting Bugs Features Accuracy AutoDock Vina significantly improves the average accuracy of the binding mode predictions compared to AutoDock 4, judging by our tests on the training set used in AutoDock 4 development.[*] Additionally and independently, AutoDock Vina has been tested against a virtual screening benchmark called the Directory of Useful Decoys by the Watowich group, and was found to be "a strong competitor against the other programs, and at the top of the pack in many cases". It should be noted that all six of the other docking programs, to which it was compared, are distributed commercially. AutoDock Tools Compatibility For its input and output, Vina uses the same PDBQT molecular structure file Binding mode prediction accuracy on the test set. format used by AutoDock. PDBQT files can be generated (interactively or in "AutoDock" refers to AutoDock 4, and "Vina" to AutoDock batch mode) and viewed using MGLTools. Other files, such as the AutoDock Vina 1. and AutoGrid parameter files (GPF, DPF) and grid map files are not needed. Ease of Use Vina's design philosophy is not to require the user to understand its implementation details, tweak obscure search parameters, cluster results or know advanced algebra (quaternions). All that is required is the structures of the molecules being docked and the specification of the search space including the binding site.
  • Structure Based Pharmacophore Modeling, Virtual Screening

    Structure Based Pharmacophore Modeling, Virtual Screening

    www.nature.com/scientificreports OPEN Structure based pharmacophore modeling, virtual screening, molecular docking and ADMET approaches for identifcation of natural anti‑cancer agents targeting XIAP protein Firoz A. Dain Md Opo1,2, Mohammed M. Rahman3*, Foysal Ahammad4, Istiak Ahmed5, Mohiuddin Ahmed Bhuiyan2 & Abdullah M. Asiri3 X‑linked inhibitor of apoptosis protein (XIAP) is a member of inhibitor of apoptosis protein (IAP) family responsible for neutralizing the caspases‑3, caspases‑7, and caspases‑9. Overexpression of the protein decreased the apoptosis process in the cell and resulting development of cancer. Diferent types of XIAP antagonists are generally used to repair the defective apoptosis process that can eliminate carcinoma from living bodies. The chemically synthesis compounds discovered till now as XIAP inhibitors exhibiting side efects, which is making difculties during the treatment of chemotherapy. So, the study has design to identifying new natural compounds that are able to induce apoptosis by freeing up caspases and will be low toxic. To identify natural compound, a structure‑ based pharmacophore model to the protein active site cavity was generated following by virtual screening, molecular docking and molecular dynamics (MD) simulation. Initially, seven hit compounds were retrieved and based on molecular docking approach four compounds has chosen for further evaluation. To confrm stability of the selected drug candidate to the target protein the MD simulation approach were employed, which confrmed stability of the three compounds. Based on the fnding, three newly obtained compounds namely Caucasicoside A (ZINC77257307), Polygalaxanthone III (ZINC247950187), and MCULE‑9896837409 (ZINC107434573) may serve as lead compounds to fght against the treatment of XIAP related cancer, although further evaluation through wet lab is necessary to measure the efcacy of the compounds.
  • Virtual Screening in Drug Design – Overview of Most Frequent Techniques

    Virtual Screening in Drug Design – Overview of Most Frequent Techniques

    Mil. Med. Sci. Lett. (Voj. Zdrav. Listy) 2016, vol. 85(2), p. 75-79 ISSN 0372-7025 DOI: 10.31482/mmsl.2016.014 REVIEW ARTICLE VIRTUAL SCREENING IN DRUG DESIGN – OVERVIEW OF MOST FREQUENT TECHNIQUES Tomas Kucera Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic Received 22 nd May 2016. Revised 5 th June 2016. Published 14 th June 2016. Summary New and modern techniques of drug design are extensively used in parallel or instead of the classic ones. Applicability of virtual screening (VS) is growing with the computational performance. This article includes list and short description of most frequent used methods in VS. These methods are divided into two groups – ligand-based VS and structure-based VS. Ligand based methods include chemical similarity, pharmacophore and quantitative structure-activity relationship. Molecular docking and scoring are methods of the structure-based VS. Key words: virtual screening, drug design, docking, scoring, pharmacophore, fingerprint, QSAR INTRODUCTION technologies and growing computational perfor - mance [2]. The VS has three main advantages – per - Drug design is a costly and time-consuming pro - formance, price and safety – compared with traditi- cess. Some new methods are carried out in parallel onal methods or with in vitro high through-put scre - or instead of the traditional ones in the process of se - ening. It enables to test large databases of compounds arching for new drugs. This new performance tech - without the necessity to hold them. A lot of com - niques are called screening methods. We can enume- pounds predicted to be inactive can be eliminated rate e.g.
  • Virtual Screening, Docking, ADMET and System Pharmacology Studies

    Virtual Screening, Docking, ADMET and System Pharmacology Studies

    www.nature.com/scientificreports OPEN Virtual screening, Docking, ADMET and System Pharmacology studies on Garcinia caged Xanthone Received: 16 November 2017 Accepted: 20 March 2018 derivatives for Anticancer activity Published: xx xx xxxx Sarfaraz Alam1,2 & Feroz Khan 1,2,3 Caged xanthones are bioactive compounds mainly derived from the Garcinia genus. In this study, a structure-activity relationship (SAR) of caged xanthones and their derivatives for anticancer activity against diferent cancer cell lines such as A549, HepG2 and U251 were developed through quantitative (Q)-SAR modeling approach. The regression coefcient (r2), internal cross-validation regression coefcient (q2) and external cross-validation regression coefcient (pred_r2) of derived QSAR models were 0.87, 0.81 and 0.82, for A549, whereas, 0.87, 0.84 and 0.90, for HepG2, and 0.86, 0.83 and 0.83, for U251 respectively. These models were used to design and screened the potential caged xanthone derivatives. Further, the compounds were fltered through the rule of fve, ADMET-risk and synthetic accessibility. Filtered compounds were then docked to identify the possible target binding pocket, to obtain a set of aligned ligand poses and to prioritize the predicted active compounds. The scrutinized compounds, as well as their metabolites, were evaluated for diferent pharmacokinetics parameters such as absorption, distribution, metabolism, excretion, and toxicity. Finally, the top hit compound 1G was analyzed by system pharmacology approaches such as gene ontology, metabolic networks, process networks, drug target network, signaling pathway maps as well as identifcation of of-target proteins that may cause adverse reactions. Cancer is a major public health problem worldwide and is the second-leading cause of death in the United States.
  • Folding-TIM Barrel

    Folding-TIM Barrel

    Protein Folding Practical September 2011 Folding up the TIM barrel Preliminary Examine the parallel beta barrel that you constructed, noting the stagger of the strands that was needed to connect the ends of the 8-stranded parallel beta sheet into the 8-stranded beta barrel. Notice that the stagger dictates which side of the sheet is on the inside and which is on the outside. This will be key information in folding the complete TIM linear peptide into the TIM barrel. Assembling the full linear peptide 1. Make sure the white beta strands are extended correctly, and the 8 yellow helices (with the green loops at each end) are correctly folded into an alpha helix (right handed with H-bonds to the 4th ahead in the chain). 2. starting with a beta strand connect an alpha helix and green loop to make the blue-red connecting peptide bond. Making sure that you connect the carbonyl (red) end of the beta strand to the amino (blue) end of the loop-helix-loop. Secure the just connected peptide bond bond with a twist-tie as shown. 3. complete step 2 for all beta strand/loop-helix-loop pairs, working in parallel with your partners 4. As pairs are completed attach the carboxy end of the strand- loop-helix-loop to the amino end of the next strand-loop-helix-loop module and secure the new peptide bond with a twist-tie as before. Repeat until the full linear TIM polypeptide chain is assembled. Make sure all strands and helices are still in the correct conformations.
  • Supplemental Table 7. Every Significant Association

    Supplemental Table 7. Every Significant Association

    Supplemental Table 7. Every significant association between an individual covariate and functional group (assigned to the KO level) as determined by CPGLM regression analysis. Variable Unit RelationshipLabel See also CBCL Aggressive Behavior K05914 + CBCL Emotionally Reactive K05914 + CBCL Externalizing Behavior K05914 + K15665 K15658 CBCL Total K05914 + K15660 K16130 KO: E1.13.12.7; photinus-luciferin 4-monooxygenase (ATP-hydrolysing) [EC:1.13.12.7] :: PFAMS: AMP-binding enzyme; CBQ Inhibitory Control K05914 - K12239 K16120 Condensation domain; Methyltransferase domain; Thioesterase domain; AMP-binding enzyme C-terminal domain LEC Family Separation/Social Services K05914 + K16129 K16416 LEC Poverty Related Events K05914 + K16124 LEC Total K05914 + LEC Turmoil K05914 + CBCL Aggressive Behavior K15665 + CBCL Anxious Depressed K15665 + CBCL Emotionally Reactive K15665 + K05914 K15658 CBCL Externalizing Behavior K15665 + K15660 K16130 KO: K15665, ppsB, fenD; fengycin family lipopeptide synthetase B :: PFAMS: Condensation domain; AMP-binding enzyme; CBCL Total K15665 + K12239 K16120 Phosphopantetheine attachment site; AMP-binding enzyme C-terminal domain; Transferase family CBQ Inhibitory Control K15665 - K16129 K16416 LEC Poverty Related Events K15665 + K16124 LEC Total K15665 + LEC Turmoil K15665 + CBCL Aggressive Behavior K11903 + CBCL Anxiety Problems K11903 + CBCL Anxious Depressed K11903 + CBCL Depressive Problems K11903 + LEC Turmoil K11903 + MODS: Type VI secretion system K01220 K01058 CBCL Anxiety Problems K11906 + CBCL Depressive